Physician profile
Manoj Rawal
NPI 1003804170
$18,834.20
in general payments reported to CMS, 2019-2025
25 companies · $4,143 in 2025
The $4,143 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $466 · 2021: $3,924 · 2022: $2,200 · 2023: $5,123 · 2024: $2,198 · 2025: $4,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,964 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,963.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,664.21 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $2,786.78 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $2,738.50 | 2021-2025 | Resolute Onyx, Symplicity G3, Closurefast |
| Abbott Laboratories | $2,604.47 | 2019-2025 | Mitraclip, Triclip, Na |
| Boston Scientific Corporation | $685.24 | 2019-2025 | General - Therapies, Watchman Flx, General - Brady |
| Novartis Pharmaceuticals Corporation | $568.75 | 2019-2024 | |
| Amgen INC. | $501.23 | 2023-2025 | Repatha, Krystexxa, Repatha |
| Zoll Circulation INC | $219.99 | 2023 | Catheter, Therox Ds2 Console, Downstream Cartridge |
| Cardiovascular Systems INC. | $211.84 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $197.85 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $105.70 | 2022-2024 | Xarelto |
| Terumo Medical Corporation | $62.99 | 2022 | |
| Cleerly, INC. | $51.70 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bardy Diagnostics, INC. | $45.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $44.44 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $42.17 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $36.40 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.29 | 2019 | |
| Inspire Medical Systems, INC. | $30.68 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $25.61 | 2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $16.52 | 2023 | Amvuttra |
| Cvrx, INC. | $15.97 | 2023 | Barostim Neo System |
| Cardiva Medical, INC. | $14.96 | 2023 | Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.